<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disease-modifying therapies for sickle cell disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disease-modifying therapies for sickle cell disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Disease-modifying therapies for sickle cell disease</div><div class="cntnt"><table cellspacing="0"><colgroup width="12%"></colgroup><colgroup span="4" width="22%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Therapy</td> <td class="subtitle1">Hydroxyurea<br/> (1998)<br/> (Siklos, Hydrea)</td> <td class="subtitle1">L-glutamine<br/> (2017)<br/> (Endari)</td> <td class="subtitle1">Voxelotor<br/> (2019, 2021)<br/> (Oxbryta)</td> <td class="subtitle1">Crizanlizumab<br/> (2019)<br/> (Adakveo)</td> </tr> <tr class="divider_bottom divider_top"> <td><strong>Age</strong></td> <td>All ages including infants</td> <td>5 years and older*</td> <td>4 years and older*</td> <td>16 years and older*</td> </tr> <tr class="divider_bottom"> <td><strong>Route</strong></td> <td>Oral (pill or liquid; liquid used for young children requires formulary preparation)</td> <td>Oral (powder added to food or beverages)</td> <td>Oral (tablet)</td> <td>Intravenous</td> </tr> <tr class="divider_bottom"> <td><strong>Frequency</strong></td> <td>Once daily</td> <td>Twice daily</td> <td>Once daily</td> <td>Once every 4 weeks (after initial dose week 0, 2, and 4)</td> </tr> <tr class="divider_bottom"> <td><strong>Monitoring</strong></td> <td>Frequent monitoring of CBC and dose titration, especially during drug initiation</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr class="divider_bottom"> <td><strong>Benefits</strong></td> <td> <ul> <li>Improved life expectancy</li> <li>Reduced acute pain episodes (4.5 versus 2.5)<sup>¶</sup></li> <li>Reduced vaso-occlusive complications including acute chest syndrome and stroke (selected individuals)</li> <li>Reduced transfusion requirement</li> <li>25 years of safety and efficacy data</li> </ul> </td> <td> <ul> <li>Reduced acute pain episodes (4 versus 3)<sup>¶</sup></li> <li>Can be combined with hydroxyurea</li> <li>Good safety profile</li> </ul> </td> <td> <ul> <li>Non-statistically significant trend towards reduced acute pain episodes (3.2 versus 2.8)<sup>¶</sup></li> <li>Can be combined with hydroxyurea</li> <li>Increased hemoglobin and decreased hemolysis</li> <li>Improved global functioning</li> <li>May improve fatigue</li> </ul> </td> <td class="divider_bottom"> <ul> <li>Reduced in acute pain episodes (3 versus 1.6)<sup>¶</sup></li> <li>Can be combined with hydroxyurea</li> <li>Good choice for severe and frequent pain episodes</li> </ul> </td> </tr> <tr> <td><strong>Caveats</strong></td> <td> <ul> <li>Hair loss</li> <li>Gastrointestinal symptoms</li> <li>Generally avoid prior to conception (males and females) and during first trimester of pregnancy</li> </ul> </td> <td> <ul> <li>Use pharmacologic grade (not over-the-counter) L-glutamine</li> <li>Mild gastrointestinal symptoms</li> <li>Long-term efficacy data are lacking</li> </ul> </td> <td> <ul> <li>Dose adjustments for CYP3A4 interactions</li> <li>Gastrointestinal symptoms</li> <li>Monitor hemoglobin in individuals with higher baseline hemoglobin (eg, HbSC disease)</li> </ul> </td> <td> <ul> <li>Requires intravenous access and hospital infusions</li> <li>Infusion reactions (rare)</li> <li>Arthralgias and back pain</li> <li>Nausea</li> <li>May cause platelet clumping in samples collected in EDTA</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">These medications are intended to be started when the individual is well; they are <strong>not appropriate</strong> for treating acute pain. Individuals with sickle cell disease may consider the information in this table or other information along with their values and preferences when determining the best therapy to use. For each drug, the year the drug was approved by the US Food and Drug Administration (FDA) and associated brand names are listed in parentheses.</div><div class="graphic_footnotes">CBC: complete blood count; EDTA: ethylenediaminetetraacetic acid.<br/>
* Refers to age listed on United States product information. At times we use these drugs in selected younger patients (off-label).<br/>
¶ Expressed as annualized rates, compared with placebo.<sup>[1-4]</sup> None of the drugs have been directly compared with each other in a randomized trial.</div><div class="graphic_reference">References:
<ol>
<li>Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.</li>
<li>Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of L-glutamine in Sickle Cell Disease. N Engl J Med 2018; 379:226.</li>
<li>Vichinsky E, Hoppe CC, Ataga KI, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med 2019; 381:509.</li>
<li>Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376:429.</li>
</ol></div><div id="graphicVersion">Graphic 127109 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
